Breaking News

XOMA Appoints Chief Commercial Officer

March 19, 2013

Klein brings 25 years of experience

Tom Klein has been appointed chief commercial officer at XOMA Corp. In this newly created position, he reports to chief executive officer John Varian. Mr. Klein has more than 25 years of successful brand commercialization leadership, with an expertise in commercializing biologics. Mr. Klein joins the company from Genentech, where he was vice president, business unit head of Virology and Specialty Care.
"We created an executive-level position for commercial operations for two reasons. First, we are at the point where we are ready to begin building XOMA's launch strategy and commercialization plans for gevokizumab. The importance of creating the sales and marketing plan for our first XOMA-developed product cannot be underestimated. We will build on Tom's vast experience to develop a launch program that maximizes the commercial potential of gevokizumab," said Mr. Varian.
He added, "The second reason was to fully integrate market analyses into our clinical development decisions. Tom will draw on his years of experience and to provide our team with the most accurate information that will guide our second, third and fourth gevokizumab indications. The team and I are looking forward to working closely with Tom to ensure gevokizumab is a commercial success."
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks